


REMARKS/ARGUMENTS


No amendments are made to the claims.

Claim Rejections 35 U.S.C. § 102(a)

Claims 3-4, 12-13, 15-18, 22-26, and 30 were rejected as allegedly being anticipated by Burk (US 6,531,504). Applicants respectfully disagree. The following are the compounds referred to Examiner as allegedly anticipating the present claims.



The following is the claimed structure:



Formula I

In the claims, “R² and R³ are C₁₋₆ linear alkyl.” Since the Burk reference does not have C₁₋₆ linear alkyl in that position, it does not anticipate the claims. Furthermore, since Burk provides no reason to make such a modification to its teachings, it does not render the claims obvious. Therefore, the claims are patentable over the prior art.

Double Patenting

The claims were rejected on nonstatutory double patenting grounds over Serial No. 10/365,369. Applicants respectfully point out that this application has issued as US Patent Number 6,875,787.

Applicants submit herewith a terminal disclaimer to US Patent Number 6,875,787. Thus, this rejection is believed to be overcome.

In light of the arguments made herein, Applicants respectfully request that the rejections be withdrawn and the application be allowed to issue.

No fee is believed due in connection with this communication. However, if applicant is in error please charge Deposit Account 01-0885 for any fees related to this response.

Dated: April 1, 2008

Respectfully submitted,

/Brent A. Johnson/
Brent A. Johnson
Registration No. 51,851
Agent of Record

Please send all inquiries and correspondence to:

Brent A. Johnson
Allergan, Inc. (T2-7H)
2525 Dupont Drive
Irvine, CA 92612
Telephone: 714/246-4348

Enclosure:

Terminal Disclaimer